Monopar Therapeutics Other Current Liab Over Time

MNPR Stock  USD 24.00  1.82  7.05%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Monopar Therapeutics Performance and Monopar Therapeutics Correlation.
To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.
  
As of 12/23/2024, Other Current Liabilities is likely to grow to about 1.8 B.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.98)
Return On Assets
(0.53)
Return On Equity
(1.02)
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Other Current Liab Analysis

Compare Monopar Therapeutics and related stocks such as Anebulo Pharmaceuticals, Acrivon Therapeutics,, and Pmv Pharmaceuticals Other Current Liab Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ANEB22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K22.6 K131.6 K131.7 K534.3 K104.2 K203.3 K
ACRV419 K419 K419 K419 K419 K419 K419 K419 K419 K419 K419 K1.2 M4.1 M6.5 M3.4 M
MOLN1.01.01.01.03.2 M3.1 M4.3 M4.5 M6.9 MM9.4 M11.6 M15.1 M12.8 M7.8 M
MLYS54 K54 K54 K54 K54 K54 K54 K54 K54 K54 K54 K4.3 M6.2 M9.9 M5.6 M
CADL1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M3.3 M3.8 M4.3 M3.8 M3.6 M
ACXP1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M455.9 K780.5 KMM1.8 M
SCPH1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M2.2 M1000353 K3.7 M4.3 M3.5 M4.7 M8.8 M9.2 M
DMAC443 K364.6 K390.7 K1.2 M850.5 K96.9 K99.9 K490 K774 K1.1 M791 K917 K1.3 M1.7 M1.8 M
KTTA6.6 K6.6 K6.6 K6.6 K6.6 K6.6 K6.6 K6.6 K6.6 K6.6 K6.6 K447.3 K235.9 K2.6 M2.7 M
ANTX108 K108 K108 K108 K108 K108 K108 K108 K108 K108 K1.3 M2.3 MM11.4 M11.9 M
PHVS78.4 K78.4 K78.4 K78.4 K78.4 K78.4 K78.4 K78.4 K235 K1.4 M4.5 M(2.5 M)10.9 M11.1 M11.6 M
PEPG185 K185 K185 K185 K185 K185 K185 K185 K185 K185 K117 K7.1 M3.1 M10.5 M11 M
AVTE115 K115 K115 K115 K115 K115 K115 K115 K115 K115 K1.2 M958 K4.4 M14.4 M15.1 M
ADAG7.4 M7.4 M7.4 M7.4 M7.4 M7.4 M7.4 M7.4 M7.4 M4.4 M8.5 M14.8 M22.2 M19.7 M14.1 M
RZLT157.8 K157.8 K157.8 K35.6 K130.4 K131.6 K58873.9 K7.3 M2.1 M403 K1.2 M1.4 M4.1 M4.3 M

Monopar Therapeutics and related stocks such as Anebulo Pharmaceuticals, Acrivon Therapeutics,, and Pmv Pharmaceuticals Other Current Liab description

My Equities

My Current Equities and Potential Positions

Monopar Therapeutics
MNPR
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationIllinois; U.S.A
ExchangeNASDAQ Exchange
USD 24.0

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.